Dermatology Times

OCTOBER 11, 2023

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Dermatitis 81

Dermatitis Sustainability Safety Treatments 81

Dermatology Times

JANUARY 16, 2024

The FDA has added efficacy and safety data for patients ages 12 years and older with uncontrolled moderate-to-severe atopic dermatitis with hand and/or foot involvement.

Dermatitis 74

Dermatitis Safety 74

The Dermatology Digest

JANUARY 22, 2025

The SNDS is supported by data from Arcutis pivotal ARRECTOR (A Randomized tRial Employing topiCal roflumilasT foam to treat scalp psORiasis) Phase 3 trial, a Phase 2b study, and long-term efficacy and safety data generated from thecream development program in plaque psoriasis. of individuals treated with vehicle. Roumilast cream 0.3%

Dermatitis 36

Dermatitis Safety Treatments Dermatology 36

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

MARCH 14, 2025

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Safety 36

Safety Dermatitis Therapy 36

Dermatology Times

MARCH 21, 2025

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Safety 36

Safety Dermatitis Treatments 36

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN. Food and Drug Administration for the treatment of AD and PN.

Dermatitis 36

Dermatitis Hospital Marketing Clinic 36

Dermatology Times

JUNE 10, 2024

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Safety 73

Safety Treatments Dermatitis 73

Dermatology Times

NOVEMBER 19, 2024

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Safety 74

Safety Dermatitis 74

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. in seborrheic dermatitis.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Dermatology Times

JANUARY 2, 2025

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36

Safety Dermatitis Management Clinic 36

The Dermatology Digest

SEPTEMBER 26, 2024

Food and Drug Administration approved for prurigo nodularis (PN), nemolizumab (Nemluvio, Galderma) improved signs and symptoms of atopic dermatitis for more than one year, according to the ARCADIA open-label extension study. The new data was presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam.

Dermatitis 74

Dermatitis Safety Management Eczema 74

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JANUARY 14, 2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. Zoryve foam; 48.3% of the total study population).

Dermatitis 72

Dermatitis Office Dermatology Safety 72

Dermatology Times

DECEMBER 11, 2023

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Safety 74

Safety Management Dermatitis 74

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

Dermatology Times

DECEMBER 18, 2023

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

Safety 74

Safety Dermatitis 74

The Dermatology Digest

FEBRUARY 10, 2025

Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegaldesleukin in AD patients were presented at the 2023 European Academy of Dermatology and Venereology Congress. FDA Fast Tracks Nektar Therapeutics AD Candidate appeared first on The Dermatology Digest. ” The post AD Pipeline Watch: U.S.

Dermatitis 36

Dermatitis Therapy Office Safety 36

Dermatology Times

MAY 13, 2024

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

Safety 74

Safety Dermatitis Treatments 74

Dermatology Times

OCTOBER 24, 2024

Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.

Safety 53

Safety Dermatitis Clinic 53

Dermatology Times

JANUARY 11, 2024

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Safety 73

Safety Dermatitis 73

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Dermatitis 36

Dermatitis Safety Education Therapy 36

The Dermatology Digest

FEBRUARY 14, 2024

and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

Dermatology Times

MARCH 14, 2025

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

Dermatology Times

OCTOBER 16, 2023

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

Dermatitis 68

Dermatitis Safety 68

Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

Dermatology Times

OCTOBER 3, 2023

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

Dermatitis 36

Dermatitis Treatments Safety Dermatology 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis.

Safety 74

Safety Office Dermatitis Clinic 74

Dermatology Times

MARCH 12, 2025

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

Dermatitis 59

Dermatitis Safety 59

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

Dermatology Times

JULY 19, 2024

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Safety 45

Safety Dermatitis 45

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

Dermatology Times

FEBRUARY 24, 2025

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

Dermatitis 36

Dermatitis Treatments Safety Management 36

Dermatology Times

MARCH 3, 2025

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Dermatitis 36

Dermatitis Treatments Safety Management 36